--- title: 'Life Sciences Daily Summary: What Happened on November 8, 2026' headline: Semaglutide lowered exercise heart pressures in an 81-person trial description: The FDA granted uniQure’s Huntington’s gene therapy priority review. A Senate discussion draft proposed new rules for software medical devices. url: https://thebench.bio/news/summaries/2026-11-08 topic: all date: '2026-11-08' covers: - '2026-11-08' date_published: '2026-11-08T12:01:05Z' date_modified: '2026-11-09T00:01:51Z' tags: - Clinical - Software - Industry - Regulatory sources: 6 publisher: TheBench.Bio --- # Life Sciences Daily Summary: What Happened on November 8, 2026 **Semaglutide lowered exercise heart pressures in an 81-person trial** The FDA granted uniQure’s Huntington’s gene therapy priority review. A Senate discussion draft proposed new rules for software medical devices. ## Today in brief In an 81-person trial, semaglutide lowered heart-filling pressure during exercise in people with obesity-related heart failure after 52 weeks. [1] The FDA granted priority review to uniQure’s application for its Huntington’s gene therapy, AMT-130. [2] Senator Bill Cassidy released a discussion draft proposing changes to FDA review of software-based and integrated medical devices. [3] ## Semaglutide lowered exercise heart pressures in an obesity-related heart-failure trial Semaglutide lowered exercise heart pressure more than placebo in a randomized trial of 81 people with obesity and heart failure after 52 weeks. [1] Average exercise pulmonary artery wedge pressure fell 9.8 mmHg with semaglutide and rose 0.9 mmHg with placebo, for an estimated between-group difference of 10.6 mmHg. [1] Hemodynamic remission, meaning an improvement in heart pressures, occurred in 53.7% of participants receiving semaglutide and 7.4% receiving placebo. [1] In a separate, prespecified magnetic resonance substudy of 49 participants, semaglutide improved measures of heart structure and function after 52 weeks. [4] The study authors said those changes may help explain the drug’s effects on heart pressures. [4] ## FDA grants uniQure’s Huntington’s gene therapy priority review The FDA accepted uniQure’s application for AMT-130 and granted it priority review. [2] The therapy uses an AAV5 vector to deliver an artificial microRNA designed to silence the Huntingtin gene. [2] AMT-130 requires neurosurgery. Some patients experienced neuroinflammation. [2] ## Senate draft proposes changes to FDA review of software medical devices Senator Bill Cassidy released a discussion draft of the PATIENT AI Act, which proposes changes to FDA review of software-based and integrated medical devices. [3] The draft would direct the FDA to create risk-based premarket review for software devices and allow certain plans for reviewing later changes. [3] It proposes voluntary preliminary review of integrated-device components, while requiring the complete device to follow an existing authorization pathway. [3] The draft would create accredited third-party review and a voluntary pilot to update postmarket surveillance. [3] The proposal’s authors said it could duplicate existing FDA processes, and its practical value would depend on implementation. [3] ## Also worth knowing - UK Research and Innovation will provide more than £52 million to five hubs developing early-detection technologies. Industry partners will add £37.5 million in cash and in-kind support. [5] - MedPharm appointed Jason Mieding chief operating officer and head of its semisolid manufacturing site, creating a new role. [6] ## The day in numbers - **−10.6 mmHg**: Estimated difference between semaglutide and placebo in the change in exercise heart-filling pressure after 52 weeks. [1] - **53.7% vs. 7.4%**: Share of participants reaching hemodynamic remission with semaglutide and placebo, respectively. [1] - **More than £52 million**: UKRI funding for five early-detection research hubs. [5] ## Sources 1. [Hemodynamic effects of semaglutide in individuals with heart failure with preserved ejection fraction and obesity: a placebo-controlled randomized clinical trial](), Nature Medicine, 2026-11-08 2. [Weekly reads: Huntington’s treatment hope, AI & the idea of a science paper, misuse of 3-parent IVF (MRT), death of young stem cell biologist](), The Niche, 2026-11-08 3. [The PATIENT AI Act: A New Prescription for FDA Software Review, or More of the Same?](), FDA Law Blog, 2026-11-08 4. [Effects of semaglutide on cardiac structure and function in heart failure with preserved ejection fraction and obesity: a pre-specified cardiac magnetic resonance substudy of the CAMEO-SEMA trial](), Nature Medicine, 2026-11-08 5. [UKRI backs five hubs developing AI tools for earlier disease detection](), Pharmafile, 2026-11-08 6. [MedPharm appoints Jason Mieding as chief operating officer](), Pharmafile, 2026-11-08 --- TheBench.Bio wrote this from the reporting cited above, with a language model drafting and editing. [1]: [2]: [3]: [4]: [5]: [6]: